Robert W. Baird Boosts Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target to $162.00

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) had its price target hoisted by investment analysts at Robert W. Baird from $154.00 to $162.00 in a note issued to investors on Monday,Benzinga reports. The brokerage presently has an "outperform" rating on the specialty pharmaceutical company's stock. Robert W. Baird's price target would indicate a potential upside of 37.77% from the stock's previous close.

Several other brokerages also recently weighed in on JAZZ. Piper Sandler reduced their price target on Jazz Pharmaceuticals from $188.00 to $166.00 and set an "overweight" rating on the stock in a report on Thursday, August 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 7th. Royal Bank of Canada boosted their price objective on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a research report on Wednesday, October 23rd. HC Wainwright reaffirmed a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Finally, TD Cowen lowered their price target on Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $175.53.

Jazz Pharmaceuticals Trading Down 3.3 %

Shares of Jazz Pharmaceuticals stock traded down $4.06 during trading on Monday, hitting $117.59. The stock had a trading volume of 642,653 shares, compared to its average volume of 678,466. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $134.17. The stock has a market cap of $7.11 billion, a PE ratio of 17.03, a PEG ratio of 1.02 and a beta of 0.57. The firm's fifty day simple moving average is $112.22 and its 200-day simple moving average is $110.35.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of the business's stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 8.85 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the company's stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. This trade represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock worth $720,160 in the last 90 days. 4.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Coldstream Capital Management Inc. grew its holdings in shares of Jazz Pharmaceuticals by 7.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 2,300 shares of the specialty pharmaceutical company's stock worth $259,000 after purchasing an additional 165 shares during the period. MidWestOne Financial Group Inc. increased its holdings in Jazz Pharmaceuticals by 5.4% during the 3rd quarter. MidWestOne Financial Group Inc. now owns 22,063 shares of the specialty pharmaceutical company's stock worth $2,458,000 after purchasing an additional 1,134 shares during the last quarter. Barclays PLC raised its position in shares of Jazz Pharmaceuticals by 19.1% in the 3rd quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock valued at $4,369,000 after purchasing an additional 6,289 shares in the last quarter. Public Employees Retirement System of Ohio purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter valued at approximately $2,491,000. Finally, XTX Topco Ltd grew its position in shares of Jazz Pharmaceuticals by 57.5% during the third quarter. XTX Topco Ltd now owns 11,631 shares of the specialty pharmaceutical company's stock worth $1,296,000 after buying an additional 4,245 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.